Track Tempest Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Tempest Therapeutics Inc. Common Stock TPST · Stock Open Tempest Therapeutics Inc. Common Stock in new tab

0.3819 USD
EPS
-3.93
P/B
-3.54
ROE
-1797.61
Beta
-1.56
Loading chart...
Key Metrics
Earnings dateMarch 29, 2027
EPS-3.93
Book Value-0.11
Price to Book-3.54
Debt/Equity955.47
% Insiders25.509%
Estimates
Forward P/E-0.32
Forward EPS-1.21

DCF valuation

Model fair value for Tempest Therapeutics Inc. Common Stock (TPST)
Result
Sign in to run the valuation for TPST.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Tempest Therapeutics Inc. Common Stock Logo Tempest Therapeutics Inc. Common Stock Analysis (TPST)

United States Health Care Official Website Stock

Is Tempest Therapeutics Inc. Common Stock a good investment? Tempest Therapeutics Inc. Common Stock (TPST) is currently trading at 0.3819 USD.

Earnings Schedule: Tempest Therapeutics Inc. Common Stock is expected to release its next earnings report on March 29, 2027. The market consensus estimate for Forward EPS is -1.21.

Investor FAQ

Does Tempest Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Tempest Therapeutics Inc. Common Stock?

Tempest Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 29, 2027. The company currently has a trailing EPS of -3.93.

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Exchange Ticker
NMS (United States) TPST
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 10, 2018 0.07
June 28, 2021 0.07
April 9, 2025 0.08
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion